A fluorinated steroid that is 9-fluoropregna-1,4-diene substituted by hydroxy groups at positions 11, 17 and 21, a methyl group at position 16 and oxo groups at positions 3 and 20. It is a synthetic member of the class of glucocorticoids.
Chemical ID:
MESH:D003907
Note: Use of the qualifier "multiple interactions" designates that the annotated interaction
is comprised of a complex set of reactions and/or regulatory events, possibly involving
additional chemicals and/or gene products.
Dexamethasone results in increased expression of PPARG mRNA; Dexamethasone results in increased expression of PPARG mRNA alternative form; Dexamethasone results in increased expression of PPARG protein
(+)-JQ1 compound inhibits the reaction [[INS1 protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Troglitazone] results in increased expression of PPARG protein]; (+)-JQ1 compound inhibits the reaction [[INS1 protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine] results in increased expression of PPARG mRNA]; (+)-JQ1 compound inhibits the reaction [Rosiglitazone promotes the reaction [[INS1 protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine] results in increased expression of PPARG mRNA]]; 14-deoxy-11,12-didehydroandrographolide inhibits the reaction [[1-Methyl-3-isobutylxanthine co-treated with Dexamethasone co-treated with INS1 protein] results in increased expression of PPARG mRNA]; 14-deoxy-11,12-didehydroandrographolide inhibits the reaction [[1-Methyl-3-isobutylxanthine co-treated with Dexamethasone co-treated with INS1 protein] results in increased expression of PPARG protein]; 2,2',3',4,4',5-hexachlorobiphenyl promotes the reaction [[Dexamethasone co-treated with INS1 protein co-treated with 1-Methyl-3-isobutylxanthine] results in increased expression of PPARG protein]; 2,2',4,4',5-brominated diphenyl ether promotes the reaction [[Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS protein] results in increased expression of PPARG mRNA]; 2,2-bis(4-glycidyloxyphenyl)propane inhibits the reaction [Dexamethasone results in increased expression of PPARG mRNA]; 2,2-bis(4-glycidyloxyphenyl)propane inhibits the reaction [Dexamethasone results in increased expression of PPARG protein]; 2-chloro-5-nitrobenzanilide inhibits the reaction [[Dexamethasone co-treated with INS1 protein co-treated with 1-Methyl-3-isobutylxanthine co-treated with perfluorooctanoic acid] results in increased expression of PPARG mRNA]; 2-chloro-5-nitrobenzanilide inhibits the reaction [[Dexamethasone co-treated with INS1 protein co-treated with 1-Methyl-3-isobutylxanthine co-treated with perfluorooctanoic acid] results in increased expression of PPARG protein]; 3,3',4,5'-tetrahydroxystilbene inhibits the reaction [[Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS protein] results in increased expression of PPARG mRNA]; 3,3',4,5'-tetrahydroxystilbene inhibits the reaction [[Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS protein] results in increased expression of PPARG protein]; 3,5,6-trichloro-2-pyridinol promotes the reaction [[Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS1 protein] results in increased expression of PPARG mRNA]; [1-Methyl-3-isobutylxanthine co-treated with Dexamethasone co-treated with INS protein co-treated with Indomethacin] results in increased expression of PPARG mRNA; [1-Methyl-3-isobutylxanthine co-treated with Dexamethasone co-treated with INS protein co-treated with Indomethacin] results in increased expression of PPARG protein; [1-Methyl-3-isobutylxanthine co-treated with Dexamethasone co-treated with INS protein] results in increased expression of PPARG mRNA; [1-Methyl-3-isobutylxanthine co-treated with Dexamethasone co-treated with INS protein] results in increased expression of PPARG protein; [1-Methyl-3-isobutylxanthine co-treated with Dexamethasone co-treated with INS1 protein] results in increased expression of PPARG mRNA; [1-Methyl-3-isobutylxanthine co-treated with Dexamethasone co-treated with INS1 protein] results in increased expression of PPARG protein; [2-ethylhexyldiphenylphosphate co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS1 protein] results in increased expression of PPARG mRNA; [2-ethylhexyldiphenylphosphate co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS1 protein] results in increased expression of PPARG protein; [[INS protein co-treated with 1-Methyl-3-isobutylxanthine co-treated with Dexamethasone] co-treated with bisphenol A] results in increased activity of PPARG protein; [Ascorbic Acid co-treated with beta-glycerophosphoric acid co-treated with Dexamethasone co-treated with INS protein] results in increased expression of PPARG mRNA; [bisphenol A co-treated with INS1 protein co-treated with 1-Methyl-3-isobutylxanthine co-treated with Dexamethasone] affects the expression of PPARG mRNA; [bisphenol A co-treated with INS1 protein co-treated with 1-Methyl-3-isobutylxanthine co-treated with Dexamethasone] affects the methylation of PPARG promoter; [bisphenol S co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS1 protein] affects the expression of PPARG protein; [Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS protein] results in increased expression of PPARG mRNA; [Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS protein] results in increased expression of PPARG protein; [Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS1 protein] results in increased expression of PPARG mRNA; [Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS1 protein] results in increased expression of PPARG protein; [Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine] results in increased expression of PPARG protein; [Dexamethasone co-treated with INS protein co-treated with 1-Methyl-3-isobutylxanthine] results in increased expression of PPARG protein; [Dexamethasone co-treated with INS protein co-treated with Pioglitazone] results in increased expression of PPARG protein; [Dexamethasone co-treated with INS protein co-treated with Ro 41-5253] results in increased expression of PPARG protein; [Dexamethasone co-treated with INS1 protein co-treated with 1-Methyl-3-isobutylxanthine co-treated with perfluorooctanoic acid] results in decreased methylation of PPARG promoter; [Dexamethasone co-treated with INS1 protein co-treated with 1-Methyl-3-isobutylxanthine co-treated with perfluorooctanoic acid] results in increased expression of PPARG mRNA; [Dexamethasone co-treated with INS1 protein co-treated with 1-Methyl-3-isobutylxanthine co-treated with perfluorooctanoic acid] results in increased expression of PPARG protein; [Dexamethasone co-treated with INS1 protein co-treated with 1-Methyl-3-isobutylxanthine] results in increased expression of PPARG protein; [Dexamethasone co-treated with INS1 protein] results in increased expression of PPARG mRNA; [Dexamethasone co-treated with Oxygen deficiency] results in increased expression of PPARG mRNA alternative form; [Dexamethasone co-treated with Rosiglitazone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS1 protein] results in increased expression of PPARG mRNA; [INS protein co-treated with 1-Methyl-3-isobutylxanthine co-treated with Dexamethasone] results in increased activity of PPARG protein; [INS protein co-treated with 1-Methyl-3-isobutylxanthine co-treated with Dexamethasone] results in increased expression of PPARG mRNA; [INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Rosiglitazone co-treated with Indomethacin] results in increased expression of PPARG mRNA; [INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Rosiglitazone co-treated with Indomethacin] results in increased expression of PPARG mRNA alternative form; [INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Rosiglitazone co-treated with Indomethacin] results in increased expression of PPARG protein; [INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine] results in increased expression of PPARG mRNA; [INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine] results in increased expression of PPARG protein; [INS1 protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Troglitazone] results in increased expression of PPARG protein; [INS1 protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine] results in increased expression of PPARG mRNA; [INS1 protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine] results in increased expression of PPARG protein; [INS1 protein co-treated with Dexamethasone] results in increased expression of PPARG mRNA; [licarin A affects the susceptibility to [INS protein co-treated with 1-Methyl-3-isobutylxanthine co-treated with Dexamethasone]] which results in increased expression of PPARG mRNA; [licarin A affects the susceptibility to [INS protein co-treated with 1-Methyl-3-isobutylxanthine co-treated with Dexamethasone]] which results in increased expression of PPARG protein; [mangiferin co-treated with 1-Methyl-3-isobutylxanthine co-treated with Dexamethasone co-treated with INS1 protein] results in increased expression of PPARG protein; [octanoic acid co-treated with Dexamethasone] results in increased expression of PPARG protein alternative form; [Rosiglitazone affects the susceptibility to [INS protein co-treated with 1-Methyl-3-isobutylxanthine co-treated with Dexamethasone]] which results in increased expression of PPARG mRNA; [Rosiglitazone affects the susceptibility to [INS protein co-treated with 1-Methyl-3-isobutylxanthine co-treated with Dexamethasone]] which results in increased expression of PPARG protein; [SB 203580 results in decreased activity of MAPK14 protein] inhibits the reaction [[octanoic acid co-treated with Dexamethasone] results in increased expression of PPARG protein alternative form]; [sodium arsenite co-treated with 1-Methyl-3-isobutylxanthine co-treated with Dexamethasone co-treated with INS1 protein] results in decreased expression of PPARG mRNA; [sodium arsenite co-treated with Palmitic Acid co-treated with 1-Methyl-3-isobutylxanthine co-treated with Dexamethasone co-treated with INS1 protein] results in decreased expression of PPARG mRNA; [tetrabromobisphenol A co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS1 protein] results in increased expression of PPARG mRNA; [Tetrachlorodibenzodioxin co-treated with EGF protein] inhibits the reaction [[Dexamethasone co-treated with Rosiglitazone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS1 protein] results in increased expression of PPARG mRNA]; [triphenyl phosphate co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS1 protein] results in increased expression of PPARG mRNA; Acrylamide promotes the reaction [[1-Methyl-3-isobutylxanthine co-treated with Dexamethasone co-treated with INS1 protein] results in increased expression of PPARG mRNA]; Acrylamide promotes the reaction [[1-Methyl-3-isobutylxanthine co-treated with Dexamethasone co-treated with INS1 protein] results in increased expression of PPARG protein]; AG 1879 inhibits the reaction [EGF protein promotes the reaction [Tetrachlorodibenzodioxin inhibits the reaction [[Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine] results in increased expression of PPARG protein]]]; andrographolide inhibits the reaction [[1-Methyl-3-isobutylxanthine co-treated with Dexamethasone co-treated with INS1 protein] results in increased expression of PPARG protein]; APCDD1 protein promotes the reaction [[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine] results in increased expression of PPARG protein]; bisphenol A inhibits the reaction [[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine] results in increased expression of PPARG mRNA alternative form]; bisphenol A promotes the reaction [[INS protein co-treated with 1-Methyl-3-isobutylxanthine co-treated with Dexamethasone] results in increased activity of PPARG protein]; boric acid inhibits the reaction [[Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS protein] results in increased expression of PPARG mRNA]; boric acid inhibits the reaction [[Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS protein] results in increased expression of PPARG protein]; butylbenzyl phthalate promotes the reaction [[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine] results in increased expression of PPARG mRNA]; butylparaben promotes the reaction [Dexamethasone results in increased expression of PPARG mRNA]; cannabidiolic acid promotes the reaction [[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine] results in increased expression of PPARG mRNA]; cannabigerol promotes the reaction [[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine] results in increased expression of PPARG mRNA]; cannabigerolic acid promotes the reaction [[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine] results in increased expression of PPARG mRNA]; Chlorpyrifos promotes the reaction [[Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS1 protein] results in increased expression of PPARG mRNA]; CTNNB1 protein promotes the reaction [boric acid inhibits the reaction [[Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS protein] results in increased expression of PPARG protein]]; CTNNB1 protein promotes the reaction [sodium pentaborate inhibits the reaction [[Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS protein] results in increased expression of PPARG protein]]; Curcumin inhibits the reaction [[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine] results in increased expression of PPARG mRNA]; Curcumin inhibits the reaction [butylbenzyl phthalate promotes the reaction [[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine] results in increased expression of PPARG mRNA]]; dibutyldichlorotin inhibits the reaction [Dexamethasone results in increased expression of PPARG protein]; Diethylhexyl Phthalate promotes the reaction [[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine] results in increased expression of PPARG mRNA alternative form]; Diethylstilbestrol inhibits the reaction [[INS protein co-treated with 1-Methyl-3-isobutylxanthine co-treated with Dexamethasone] results in increased activity of PPARG protein]; dorsomorphin inhibits the reaction [rotenoisin A inhibits the reaction [[INS1 protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine] results in increased expression of PPARG protein]]; EGF protein inhibits the reaction [[Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine] results in increased expression of PPARG protein]; EGF protein promotes the reaction [Tetrachlorodibenzodioxin inhibits the reaction [[Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine] results in increased expression of PPARG protein]]; EGF protein promotes the reaction [Vanadates inhibits the reaction [[Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine] results in increased expression of PPARG protein]]; Ethanol inhibits the reaction [[INS protein co-treated with 1-Methyl-3-isobutylxanthine co-treated with Dexamethasone] results in increased expression of PPARG mRNA]; GHRL protein inhibits the reaction [[INS protein co-treated with 1-Methyl-3-isobutylxanthine co-treated with Dexamethasone] results in increased expression of PPARG mRNA]; Glycyrrhizic Acid inhibits the reaction [[Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS1 protein] results in increased expression of PPARG mRNA]; hispidulin inhibits the reaction [[1-Methyl-3-isobutylxanthine co-treated with Dexamethasone co-treated with INS protein co-treated with Indomethacin] results in increased expression of PPARG mRNA]; hispidulin inhibits the reaction [[1-Methyl-3-isobutylxanthine co-treated with Dexamethasone co-treated with INS protein co-treated with Indomethacin] results in increased expression of PPARG protein]; Ivermectin inhibits the reaction [[1-Methyl-3-isobutylxanthine co-treated with Dexamethasone co-treated with INS1 protein] results in increased expression of PPARG protein]; IWR-1 compound inhibits the reaction [Raloxifene Hydrochloride inhibits the reaction [[1-Methyl-3-isobutylxanthine co-treated with Dexamethasone co-treated with INS1 protein] results in increased expression of PPARG protein]]; JMJD6 mutant form inhibits the reaction [[INS1 protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Troglitazone] results in increased expression of PPARG protein]; methyl-beta-cyclodextrin inhibits the reaction [EGF protein promotes the reaction [Tetrachlorodibenzodioxin inhibits the reaction [[Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine] results in increased expression of PPARG protein]]]; pentagalloylglucose inhibits the reaction [[1-Methyl-3-isobutylxanthine co-treated with Dexamethasone co-treated with INS protein] results in increased expression of PPARG mRNA]; pentagalloylglucose inhibits the reaction [[1-Methyl-3-isobutylxanthine co-treated with Dexamethasone co-treated with INS protein] results in increased expression of PPARG protein]; potassium chromate(VI) inhibits the reaction [[INS1 protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine] results in increased expression of PPARG protein]; Quercetin inhibits the reaction [[Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS1 protein] results in increased expression of PPARG protein]; Raloxifene Hydrochloride inhibits the reaction [[1-Methyl-3-isobutylxanthine co-treated with Dexamethasone co-treated with INS1 protein] results in increased expression of PPARG protein]; Rifampin inhibits the reaction [[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Rosiglitazone co-treated with Indomethacin] results in increased expression of PPARG mRNA alternative form]; Rifampin inhibits the reaction [[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Rosiglitazone co-treated with Indomethacin] results in increased expression of PPARG mRNA]; Rifampin inhibits the reaction [[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Rosiglitazone co-treated with Indomethacin] results in increased expression of PPARG protein]; Ritonavir inhibits the reaction [[INS1 protein co-treated with 1-Methyl-3-isobutylxanthine co-treated with Dexamethasone] results in increased expression of PPARG protein]; Rosiglitazone promotes the reaction [[Ascorbic Acid co-treated with beta-glycerophosphoric acid co-treated with Dexamethasone co-treated with INS protein] results in increased expression of PPARG mRNA]; Rosiglitazone promotes the reaction [[Dexamethasone co-treated with INS1 protein co-treated with 1-Methyl-3-isobutylxanthine] results in increased expression of PPARG mRNA]; Rosiglitazone promotes the reaction [[Dexamethasone co-treated with INS1 protein co-treated with 1-Methyl-3-isobutylxanthine] results in increased expression of PPARG protein]; Rosiglitazone promotes the reaction [[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine] results in increased expression of PPARG mRNA]; Rosiglitazone promotes the reaction [[INS1 protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine] results in increased expression of PPARG mRNA]; rotenoisin A inhibits the reaction [[INS1 protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine] results in increased expression of PPARG mRNA]; rotenoisin A inhibits the reaction [[INS1 protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine] results in increased expression of PPARG protein]; Silybin inhibits the reaction [[1-Methyl-3-isobutylxanthine co-treated with Dexamethasone co-treated with INS1 protein] results in increased expression of PPARG protein]; sodium arsenite inhibits the reaction [[Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS1 protein] results in increased expression of PPARG mRNA]; sodium arsenite inhibits the reaction [[INS1 protein co-treated with Dexamethasone] results in increased expression of PPARG mRNA]; sodium pentaborate inhibits the reaction [[Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS protein] results in increased expression of PPARG mRNA]; sodium pentaborate inhibits the reaction [[Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS protein] results in increased expression of PPARG protein]; T 0070907 inhibits the reaction [[[INS protein co-treated with 1-Methyl-3-isobutylxanthine co-treated with Dexamethasone] co-treated with bisphenol A] results in increased activity of PPARG protein]; Tetrachlorodibenzodioxin inhibits the reaction [[Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine] results in increased expression of PPARG protein]; Tetrachlorodibenzodioxin inhibits the reaction [[Dexamethasone co-treated with Rosiglitazone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS1 protein] results in increased expression of PPARG mRNA]; TGFB1 inhibits the reaction [[Dexamethasone co-treated with INS1 protein] results in increased expression of PPARG mRNA]; TNF inhibits the reaction [[Dexamethasone co-treated with INS1 protein] results in increased expression of PPARG mRNA]; Tretinoin inhibits the reaction [[Ascorbic Acid co-treated with beta-glycerophosphoric acid co-treated with Dexamethasone co-treated with INS protein] results in increased expression of PPARG mRNA]; tributyltin promotes the reaction [[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine] results in increased expression of PPARG mRNA alternative form]; triphenyltin chloride inhibits the reaction [Dexamethasone results in increased expression of PPARG protein]; U 0126 inhibits the reaction [EGF protein promotes the reaction [Tetrachlorodibenzodioxin inhibits the reaction [[Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine] results in increased expression of PPARG protein]]]
[INS co-treated with 1-Methyl-3-isobutylxanthine co-treated with Dexamethasone] results in increased expression of PPARG mRNA; Dexamethasone inhibits the reaction [Trinitrobenzenesulfonic Acid results in decreased expression of PPARG mRNA]; Dexamethasone inhibits the reaction [Trinitrobenzenesulfonic Acid results in decreased expression of PPARG protein]
[Ascorbic Acid co-treated with beta-glycerophosphoric acid co-treated with Dexamethasone co-treated with INS protein] results in increased expression of PPARG mRNA; [Bismuth affects the susceptibility to [INS protein co-treated with Dexamethasone co-treated with Indomethacin co-treated with 1-Methyl-3-isobutylxanthine]] which results in decreased expression of PPARG mRNA; [bisphenol F co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS protein] results in increased expression of PPARG mRNA; [bisphenol F co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS protein] results in increased expression of PPARG protein; [bisphenol S co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS protein] affects the expression of PPARG protein; [bisphenol S co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS protein] results in increased expression of PPARG mRNA; [Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS protein] results in increased expression of PPARG mRNA; [Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine] results in increased expression of PPARG mRNA; [Dexamethasone co-treated with INS protein co-treated with Pioglitazone] results in increased expression of PPARG protein; [Dexamethasone co-treated with INS protein co-treated with Ro 41-5253] results in increased expression of PPARG protein; [Dexamethasone co-treated with Insulin co-treated with Indomethacin co-treated with 1-Methyl-3-isobutylxanthine] results in increased expression of PPARG mRNA; [Dichlorodiphenyl Dichloroethylene co-treated with [1-Methyl-3-isobutylxanthine co-treated with Dexamethasone co-treated with INS protein]] results in increased expression of PPARG mRNA; [Glucose co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS1 protein] results in increased expression of PPARG mRNA; [Indomethacin co-treated with Dexamethasone co-treated with INS protein] results in increased expression of PPARG mRNA; [Indomethacin co-treated with Dexamethasone co-treated with INS protein] results in increased expression of PPARG protein; [INS protein co-treated with 1-Methyl-3-isobutylxanthine co-treated with Dexamethasone co-treated with Rosiglitazone co-treated with 4,4'-hexafluorisopropylidene diphenol] results in increased expression of PPARG mRNA; [INS protein co-treated with 1-Methyl-3-isobutylxanthine co-treated with Dexamethasone co-treated with Rosiglitazone] results in increased expression of PPARG mRNA; [INS protein co-treated with 1-Methyl-3-isobutylxanthine co-treated with Dexamethasone co-treated with Rosiglitazone] results in increased expression of PPARG protein; [INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin] results in increased expression of PPARG mRNA; [Rosiglitazone co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS protein] results in increased expression of PPARG mRNA; [Rosiglitazone co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS protein] results in increased expression of PPARG protein; [Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in increased expression of PPARG mRNA; [Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in increased expression of PPARG protein; [Vitamin D co-treated with bisphenol A co-treated with 1-Methyl-3-isobutylxanthine co-treated with Dexamethasone co-treated with INS protein] affects the expression of PPARG mRNA; avobenzone promotes the reaction [[Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS protein] results in increased expression of PPARG mRNA]; avobenzone promotes the reaction [[Glucose co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS1 protein] results in increased expression of PPARG mRNA]; cordycepin inhibits the reaction [[Dexamethasone co-treated with Insulin co-treated with Indomethacin co-treated with 1-Methyl-3-isobutylxanthine] results in increased expression of PPARG mRNA]; Diethylhexyl Phthalate promotes the reaction [[Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS protein] results in increased expression of PPARG mRNA]; dioxybenzone promotes the reaction [[Glucose co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS1 protein] results in increased expression of PPARG mRNA]; octocrylene promotes the reaction [[Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS protein] results in increased expression of PPARG mRNA]; oxybenzone promotes the reaction [[Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS protein] results in increased expression of PPARG mRNA]; oxybenzone promotes the reaction [[Glucose co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS1 protein] results in increased expression of PPARG mRNA]; PPARG protein results in decreased susceptibility to [INS protein co-treated with 1-Methyl-3-isobutylxanthine co-treated with Dexamethasone]; Rosiglitazone promotes the reaction [[Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine] results in increased expression of PPARG mRNA]; Rosmarinic Acid inhibits the reaction [[Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in increased expression of PPARG protein]; TGFB1 protein inhibits the reaction [[Rosiglitazone co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS protein] results in increased expression of PPARG mRNA]
